Messenger RNA (mRNA) therapeutics hold significant promise for the future of personalized cancer treatment, but persistent ...

The U.S. government is divesting from mRNA vaccines, but will other uses of the technology be spared? In a time of ...

Artificial intelligence is getting really good at helping doctors diagnose problems and even discover new drugs faster. It ...

Messenger RNA, or mRNA, vaccines entered the public consciousness when they were introduced during the COVID-19 pandemic, and both Pfizer-BioNTech and Moderna used the technology in developing their ...

RNA COVID-19 vaccines — originally developed to protect against the coronavirus — may be providing an additional, unexpected health advantage.

However, the research team head cautioned that it is still too early to recommend the mRNA COVID-19 vaccine as a standard part of cancer therapy.

As BioNTech works to establish a production footprint for mRNA vaccines in Africa, two EU groups have offered financial backing to the company's efforts. The European Commission pledged a 35 million ...

Messenger RNA, or mRNA, vaccines entered the public consciousness when they were introduced during the COVID-19 pandemic, and both Pfizer-BioNTech and Moderna used the technology in developing their ...

Moderna (MRNA) reached $26.74 at the closing of the latest trading day, reflecting a +1.87% change compared to its last close.

In the latest trading session, Moderna (MRNA) closed at $26.85, marking a -2.33% move from the previous day. The stock's performance was behind the S&P 500's daily loss of 0.53%. Elsewhere, the Dow ...